DoxorubicinAntibiotics, AntineoplasticInduction ChemotherapyAntineoplastic Combined Chemotherapy ProtocolsTaxoidsAntineoplastic AgentsCisplatinCombined Modality TherapyCell Line, TumorCyclophosphamideDrug Resistance, NeoplasmRemission InductionChemotherapy, AdjuvantTreatment OutcomePaclitaxelApoptosisDisease-Free SurvivalBreast NeoplasmsCaspase 12EtoposideDrug Administration ScheduleTumor Suppressor Protein p53Survival AnalysisAntineoplastic Agents, PhytogenicNeoplasm StagingSurvival RateNeoadjuvant TherapyLung NeoplasmsVinblastineDaunorubicinCytarabineFluorouracilHead and Neck NeoplasmsIfosfamideVincristineCarcinoma, Squamous CellCarboplatinCardiomyopathiesBleomycinPrognosisMethotrexateMitochondria, HeartLeukemia, Myeloid, AcuteDNA DamageDose-Response Relationship, DrugCarcinoma, Non-Small-Cell LungNeoplasm Recurrence, LocalNeoplasm MetastasisDeoxycytidineNeutropeniaTumor Markers, BiologicalRNA, MessengerPrecursor Cell Lymphoblastic Leukemia-LymphomaGene Expression Regulation, NeoplasticRNA, Small InterferingMyocardiumTime FactorsSignal TransductionHeartP-GlycoproteinRadiotherapy, AdjuvantMitoxantroneAdenocarcinomaFollow-Up StudiesGranulocyte Colony-Stimulating FactorKaplan-Meier EstimateRadiotherapyInfusions, IntravenousChemoradiotherapyEnzyme InductionSalvage TherapyMelphalanRadiotherapy DosageAsparaginaseIdarubicinTumor BurdenLymphoma, Non-HodgkinBone NeoplasmsNeoplasmsBrain NeoplasmsLeukopeniaTransplantation, AutologousAnthracyclinesLomustineProspective StudiesDisease ProgressionLeukemia, MyeloidHypopharyngeal NeoplasmsEpirubicinAntimetabolites, AntineoplasticTumor Necrosis Factor-alphaLaryngectomyVindesineDrug SynergismAntibodies, MonoclonalTesticular NeoplasmsWilms TumorDrug Resistance, MultipleDexamethasoneNasopharyngeal Neoplasms